The brief overview, antivirus and anti-SARS-CoV-2 activity, quantitative methods, and pharmacokinetics of cepharanthine: a potential small-molecule drug against …
B Xia, L Zheng, Y Li, W Sun, Y Liu, L Li… - Frontiers in …, 2023 - frontiersin.org
To effectively respond to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2),
an increasing number of researchers are focusing on the antiviral activity of cepharanthine …
an increasing number of researchers are focusing on the antiviral activity of cepharanthine …
In vitro generated antibodies guide thermostable ADDomer nanoparticle design for nasal vaccination and passive immunization against SARS-CoV-2
Background Due to COVID-19, pandemic preparedness emerges as a key imperative,
necessitating new approaches to accelerate development of reagents against infectious …
necessitating new approaches to accelerate development of reagents against infectious …
A Multi-Faceted Binding Assessment of Aptamers Targeting the SARS-CoV-2 Spike Protein
L Civit, N Moradzadeh, A Jonczyk… - International Journal of …, 2024 - mdpi.com
The COVID-19 pandemic has underscored the critical need for the advancement of
diagnostic and therapeutic platforms. These platforms rely on the rapid development of …
diagnostic and therapeutic platforms. These platforms rely on the rapid development of …
Safety and Effectiveness of Regdanvimab for COVID-19 Treatment: A Phase 4 Post-marketing Surveillance Study Conducted in South Korea
JY Lee, SH Bu, EH Song, S Cho, S Yu, J Kim… - Infectious Diseases and …, 2023 - Springer
Introduction Regdanvimab, a neutralising monoclonal antibody (mAb) against severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2), received approval for the treatment of …
respiratory syndrome coronavirus 2 (SARS-CoV-2), received approval for the treatment of …
Clinical and laboratory considerations: determining an antibody-based composite correlate of risk for reinfection with SARS-CoV-2 or severe COVID-19
S Holdenrieder, CE dos Santos Ferreira… - Frontiers in Public …, 2023 - frontiersin.org
Much of the global population now has some level of adaptive immunity to SARS-CoV-2
induced by exposure to the virus (natural infection), vaccination, or a combination of both …
induced by exposure to the virus (natural infection), vaccination, or a combination of both …
SARS-CoV-2 Specific Nanobodies Neutralize Different Variants of Concern and Reduce Virus Load in the Brain of h-ACE2 Transgenic Mice
MF Pavan, M Bok, R Betanzos San Juan, JP Malito… - Viruses, 2024 - mdpi.com
Since the beginning of the COVID-19 pandemic, there has been a significant need to
develop antivirals and vaccines to combat the disease. In this work, we developed llama …
develop antivirals and vaccines to combat the disease. In this work, we developed llama …
Development of potent pan‐coronavirus fusion inhibitors with a new design strategy
Y Zhu, Z Gao, X Feng, L Cheng, N Liu, C Liu… - MedComm, 2024 - Wiley Online Library
Abstract Development of potent and broad‐spectrum drugs against severe acute respiratory
syndrome coronavirus 2 (SARS‐CoV‐2) remains one of the top priorities, especially in the …
syndrome coronavirus 2 (SARS‐CoV‐2) remains one of the top priorities, especially in the …